Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Haacke

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Klinische Wochenschrift|April 17, 1979
Spontaneous rupture of the Achilles tendon - a sign of hyperlipoproteinaemia (HLP) type IIH Haacke, M R Parwaresch
Deutsche Medizinische Wochenschrift (1946)|May 10, 1991
[Cholestatic jaundice during lovastatin medication]U Spreckelsen, R Kirchhoff, H Haacke
Medizinische Klinik|July 8, 1977
[Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)]H Haacke, M R Parwaresch, C Mäder
Deutsche Medizinische Wochenschrift (1946)|September 24, 1976
[Xantinol-nicotinate in primary type-V hyperlipoproteinaemia (author's transl)]H Haacke, M R Parwaresch, C Mäder
Klinische Wochenschrift|December 1, 1975
[Lipid constellation in low density lipoproteins of primary type II hyperlipoproteinemia (author's transl)]H Haacke, M R Parwaresch, C Mäder
Atherosclerosis|December 1, 1978
Efficacy of hypolipidemic treatment in inhibition of experimental atherosclerosis: the effect of nicotinic acid and related compoundsM R Parwaresch, H Haacke, C Mäder
Atherosclerosis|September 1, 1980
Serum profile of non-esterified fatty acids (NEFA) in patients with hyperlipoproteinemia under xantinol--nicotinate (XN) medicationH Haacke, M R Parwaresch, C Mäder
Arzneimittel-Forschung|January 1, 1976
Interaction of pentobarbital, diphenylhydantoin and digitoxin with ethanol in the isolated perfused guinea-pig liverH Haacke, K Johnsen, K D Kolenda
Klinische Wochenschrift|May 15, 1976
[Corneal arcus and hyperlipoproteinemia (author's transl)]M R Parwaresch, H Haacke, C Mäder, et al.
Atherosclerosis|February 1, 1988
Decrease in LDL and increase in HDL concentrations in type II hyperlipoproteinaemic patients on low-dose combination therapy of cholestyramine and ComplaminR Fears, H Ferres, H Haacke, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Klinische Wochenschrift|April 17, 1979
Spontaneous rupture of the Achilles tendon - a sign of hyperlipoproteinaemia (HLP) type IIH Haacke, M R Parwaresch
Deutsche Medizinische Wochenschrift (1946)|May 10, 1991
[Cholestatic jaundice during lovastatin medication]U Spreckelsen, R Kirchhoff, H Haacke
Medizinische Klinik|July 8, 1977
[Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)]H Haacke, M R Parwaresch, C Mäder
Deutsche Medizinische Wochenschrift (1946)|September 24, 1976
[Xantinol-nicotinate in primary type-V hyperlipoproteinaemia (author's transl)]H Haacke, M R Parwaresch, C Mäder
Klinische Wochenschrift|December 1, 1975
[Lipid constellation in low density lipoproteins of primary type II hyperlipoproteinemia (author's transl)]H Haacke, M R Parwaresch, C Mäder
Atherosclerosis|December 1, 1978
Efficacy of hypolipidemic treatment in inhibition of experimental atherosclerosis: the effect of nicotinic acid and related compoundsM R Parwaresch, H Haacke, C Mäder
Atherosclerosis|September 1, 1980
Serum profile of non-esterified fatty acids (NEFA) in patients with hyperlipoproteinemia under xantinol--nicotinate (XN) medicationH Haacke, M R Parwaresch, C Mäder
Arzneimittel-Forschung|January 1, 1976
Interaction of pentobarbital, diphenylhydantoin and digitoxin with ethanol in the isolated perfused guinea-pig liverH Haacke, K Johnsen, K D Kolenda
Klinische Wochenschrift|May 15, 1976
[Corneal arcus and hyperlipoproteinemia (author's transl)]M R Parwaresch, H Haacke, C Mäder, et al.
Atherosclerosis|February 1, 1988
Decrease in LDL and increase in HDL concentrations in type II hyperlipoproteinaemic patients on low-dose combination therapy of cholestyramine and ComplaminR Fears, H Ferres, H Haacke, et al.
Pageof 1